Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity Ex Vivo and In Vivo

An ability to activate latent human immunodeficiency virus type 1 (HIV-1) expression could benefit many HIV cure strategies; however, most latency-reversing agents (LRAs) have proven disappointing. We evaluated AKT/mTOR activators as a potential new class of LRAs. Two glycogen synthase kinase-3 inhi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Virol
Hlavní autoři: Gramatica, Andrea, Schwarzer, Roland, Brantley, William, Varco-Merth, Benjamin, Sperber, Hannah S., Hull, Philip A., Montano, Mauricio, Migueles, Stephen A., Rosenthal, Danielle, Hogan, Louise E., Johnson, Jeffrey R., Packard, Thomas A., Grimmett, Zachary W., Herzig, Eytan, Besnard, Emilie, Nekorchuk, Michael, Hsiao, Feng, Deeks, Steven G., Snape, Michael, Kiernan, Bernard, Roan, Nadia R., Lifson, Jeffrey D., Estes, Jacob D., Picker, Louis J., Verdin, Eric, Krogan, Nevan J., Henrich, Timothy J., Connors, Mark, Ott, Melanie, Pillai, Satish K., Okoye, Afam A., Greene, Warner C.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2021
Témata:
Vaccines and Antiviral Agents
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8103695/
https://ncbi.nlm.nih.gov/pubmed/33536176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.02393-20
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky